Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note released on Tuesday,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Separately, Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 6th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Anixa Biosciences presently has a consensus rating of “Buy” and an average target price of $9.00.

Anixa Biosciences Stock Performance

ANIX stock opened at $2.97 on Tuesday. The company has a market capitalization of $95.67 million, a price-to-earnings ratio of -7.82 and a beta of 0.43. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $4.20. The stock has a fifty day moving average of $3.25 and a 200-day moving average of $2.98.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Equities analysts predict that Anixa Biosciences will post -0.41 EPS for the current year.

Insider Transactions at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the company’s stock in a transaction on Thursday, July 31st. The stock was acquired at an average cost of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the director directly owned 953,334 shares in the company, valued at $2,936,268.72. This trade represents a 1.06% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Amit Kumar purchased 10,000 shares of the business’s stock in a transaction on Wednesday, June 4th. The stock was bought at an average cost of $2.85 per share, with a total value of $28,500.00. Following the purchase, the chief executive officer owned 569,925 shares in the company, valued at approximately $1,624,286.25. This represents a 1.79% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 45,000 shares of company stock valued at $139,200. Corporate insiders own 25.30% of the company’s stock.

Institutional Trading of Anixa Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $33,000. Millennium Management LLC purchased a new stake in shares of Anixa Biosciences during the 4th quarter valued at $26,000. Benjamin Edwards Inc. purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $37,000. Marshall Wace LLP purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $39,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Anixa Biosciences during the 1st quarter valued at $35,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.